Early Administration of Bamlanivimab in Combination with Etesevimab Increases the Benefits of COVID-19 Treatment: Real-World Experience from the Liguria Region

Monoclonal antibodies, such as bamlanivimab and etesevimab combination (BEC), have been proposed for patients with mild or moderate coronavirus disease 2019 (COVID-19). However, few studies have assessed the factors associated with the early administration of BEC or the impact of early BEC treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Vena, Antonio, Cenderello, Giovanni, Balletto, Elisa, Mezzogori, Laura, Santagostino Barbone, Alessandro, Berruti, Marco, Ball, Lorenzo, Battaglini, Denise, Bonsignore, Alessandro, Dentone, Chiara, Giacobbe, Daniele Roberto, Eldin, Tarek Kamal, Mikulska, Malgorzata, Rebesco, Barbara, Robba, Chiara, Scintu, Ambra, Stimamiglio, Andrea, Taramasso, Lucia, Pelosi, Paolo, Artioli, Stefania, Bassetti, Matteo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8538905/
https://www.ncbi.nlm.nih.gov/pubmed/34682805
http://dx.doi.org/10.3390/jcm10204682

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8538905/
https://www.ncbi.nlm.nih.gov/pubmed/34682805
http://dx.doi.org/10.3390/jcm10204682

Ejemplares similares